Meeting
2013 ASCO Annual Meeting
Chimeric antigen receptor (CAR+) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC).
Authors
Susan F. Slovin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; Memorial Sloan-Kettering Cancer Center, New York, NY
Susan F. Slovin , Xiuyan Wang , Melanie Hullings , Gabrielle Arauz , Shirley Bartido , Jason Stuart Lewis , Heiko Schöder , Pat Zanzonico , Howard I. Scher , Isabelle Riviere
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCTO1140373
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS3115)
DOI
10.1200/jco.2013.31.15_suppl.tps3115
Abstract #
TPS3115
Poster Bd #
23B
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC).
First Author: Susan F. Slovin
Poster
2022 ASCO Genitourinary Cancers Symposium
Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC.
First Author: Meredith McKean
Poster
2021 Genitourinary Cancers Symposium
A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.
First Author: Vivek Narayan
Poster
2016 Genitourinary Cancers Symposium
A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa).
First Author: Michael J. Morris